1D-LSD 10 MCG Pellets – Microdose Product Description

Introduction

1D-LSD, chemically known as 1-(1,2-dimethylcyclobutane-1-carbonyl)-lysergic acid diethylamide, is a semi-synthetic lysergamide and a novel structural analog of LSD (lysergic acid diethylamide). The compound features a dimethylcyclobutane group attached via a carbonyl linker to the nitrogen-1 position of the lysergic acid core, differentiating it from conventional LSD and other N1-acylated derivatives. 1D-LSD is provided as 10 microgram pellets intended for precise microdosing in laboratory research, where it is used to study psychedelic mechanisms and neuropharmacology with controlled dosing.

Chemical Properties and Specifications

Structural and Molecular Characteristics

• Chemical Formula: C27H35N3O2

• Molecular Weight: Approximately 433.55 g/mol

• CAS Number: Not widely assigned; research chemical status

• IUPAC Name: (8β)-1-(1,2-dimethylcyclobutane-1-carbonyl)-N,N-diethyl-6-methyl-9,10-didehydroergoline-8-carboxamide

• Synonyms: 1D-LSD, 1-(1,2-dimethylcyclobutane-1-carbonyl)-LSD

Physical Properties and Purity Standards

• Appearance: Small microdose pellets containing 10 micrograms of pure 1D-LSD, designed for accurate dosing in research. The raw compound is a crystalline solid prior to pellet formation.

• Purity: High-purity, typically ≥ 98%, suitable for rigorous scientific studies.

• Solubility: Soluble in organic solvents such as ethanol, methanol, and acetonitrile; minimal solubility in water.

• Storage Recommendations: Store in sealed, opaque containers under dry, cool, and dark conditions to preserve stability, ideally refrigerated.

Pharmacological Profile and Mechanism of Action

Proposed Mechanism of Action

1D-LSD functions as an agonist at the serotonin 5-HT2A receptor subtype, which is primarily responsible for classical psychedelic effects. Like other N1-substituted lysergamides, it is believed to act as a prodrug; enzymatic metabolism in vivo likely converts 1D-LSD to LSD, which then modulates serotonin receptor activity leading to psychedelic pharmacological outcomes. Laboratory data from animal models confer typical psychedelic behavioral profiles with altered potency and duration compared to LSD.

Research Applications

1D-LSD is used extensively in neuropharmacological and receptor binding studies, focusing on the impact of N1 substitutions on potency, metabolism, and receptor selectivity. The microdose pellet form allows finely-tuned dosing studies, essential for microdose research exploring sub-perceptual effects on cognition and neural circuitry. Its unique chemical structure advances the understanding of structure-activity relationships and prodrug dynamics in LSD analogs.

Comparative Analysis with Related Compounds

Comparison with Related Compounds

1D-LSD is structurally similar to other acylated LSD derivatives such as 1B-LSD and 1cP-LSD but features a distinctive dimethylcyclobutane carbonyl group, which influences pharmacokinetics and receptor interaction patterns. Compared to parent LSD, 1D-LSD likely shows differing potency and metabolic rates while maintaining the classic psychedelic receptor target profile.

Advantages for Research

The 10 microgram pellet format offers precise microdosing control, ideal for subtle pharmacological investigations. The unique bulky N1 substitution provides a valuable molecular tool to study how structural changes at nitrogen-1 affect LSD’s pharmacological and metabolic properties, enriching psychedelic research and simulated therapeutic studies.

Safety and Handling Guidelines

Laboratory Safety

Operate using standard safety measures including PPE (gloves, eye protection, lab coats). Handle in ventilated areas or fume hoods to prevent inhalation and accidental exposure. Avoid contact with skin and eyes.

Disposal and Environmental Considerations

Dispose of chemical waste according to hazardous materials regulations. Prevent environmental contamination through proper containment and neutralization methods.

Regulatory Status

1D-LSD is classified as a research chemical, governed by local controlled substance regulations. It is for laboratory research use only and not approved for human consumption.

Frequently Asked Questions (FAQs)

1. What dosing form does 1D-LSD come in?

• Typically as 10 mcg microdose pellets for research.

2. How stable is 1D-LSD?

• Stable when stored cool, dry, dark, and sealed.

3. Does 1D-LSD metabolize into LSD?

• It is considered a prodrug that enzymatically converts to LSD in vivo.

4. What is the solubility of 1D-LSD?

• Soluble in common organic solvents, poorly soluble in water.

5. Is 1D-LSD legal to use?

• Legal status varies; generally restricted to research only in many jurisdictions.

Conclusion

1D-LSD 10 MCG Pellets represent a novel N1-substituted lysergamide derivative of LSD, optimized for microdose research. Their high purity, precise dosing, and distinctive structural modification support advanced investigations of psychedelic pharmacology, receptor dynamics, and prodrug metabolism within controlled scientific environments.